Human papillomaviruses (HPVs) cause approximately 5% of cancer cases worldwide. Fortunately, three prophylactic vaccines have been approved to protect against HPV infections. Gardasil-9, the most recent HPV vaccine, is predicted to offer protection against the HPV types that cause~90% of cervical cancer, 86% of HPV-associated penile cancers, and~93% of HPV-associated head & neck cancers. As an alternative to Gardasil-9, we developed and tested a novel candidate vaccine targeting conserved epitopes in the HPV minor capsid protein, L2. We displayed a tandem HPV31/16L2 peptide (amino acid 17e31) or consensus peptides from HPV L2 (amino acid 69e86 or 108e122) on the surface of bacteriophage MS2 virus-like particles (VLPs). Mice immunized with the MS2 VLPs displaying the tandem peptide or immunized with a mixture of VLPs (displaying the tandem peptide and consensus peptide 69e86) elicited high titer antibodies against individual L2 epitopes. Moreover, vaccinated mice were protected from cervicovaginal infection with HPV pseudoviruses 16, 31, 45, 58 and sera from immunized mice neutralized HPV pseudoviruses 18 and 33 at levels similar to mice immunized with Gardasil-9. These results suggest that immunization with a tandem, L2 peptide or a low valency mixture of L2 peptide-displaying VLPs can provide broad protection against multiple HPV types.
Introduction
Human papillomaviruses (HPVs) are the most common sexually transmitted infections; approximately 40 HPV types can be transmitted sexually and they cause neoplasias such as genital warts and cancers (Schwarz et al., 2005; Matsukura and Sugase, 2001 ). Persistent infection with high-risk HPV (HR-HPV) types (HPV16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 70, 73, 82 ) is associated with~94% of anal cancers,~63% of penile cancers,~74% of vaginal cancers,~5e20% of head & neck squamous cell carcinomas, and nearly all cases of cervical cancers (Crow, 2012; Zhai and Tumban, 2016; Boscolo-Rizzo et al., 2013) . Infections with lowrisk HPV types (HPV6, 11, 43, and 44) are associated with genital warts (Munoz et al., 2003; Dickens et al., 1991; Sanchez et al., 2013) . HPV-associated cancers can be initiated by infection with a single HR-HPV type or by infection with multiple HR-HPV types (Schmitt et al., 2010 (Schmitt et al., , 2013 ; a situation that occurs especially in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. HIV/AIDS patients are more susceptible to HPV-associated cancers compared to non-HIV infected patients (Munoz et al., 2004; Schmitt et al., 2010; Levi et al., 2002; McKenzie et al., 2014; Beachler et al., 2012; Ortiz et al., 2014) . Thus, these patients need broad protection from infections by multiple HPV types.
Three prophylactic vaccines (Cervarix, Gardasil-4 and Gardasil-9) have been approved to protect against certain types of HPV infections. The vaccines are composed of virus-like particles (VLPs) derived from HPV major capsid protein (L1). The vaccines are highly immunogenic. However, because L1 neutralizing epitopes are not highly conserved among HPV types, L1 vaccines protect mostly against the HPV types included in the vaccines, with minimal crossprotection against non-vaccine HPV types Joura et al., 2015; Smith et al., 2007; Toft et al., 2014; Wheeler et al., 2009) . For example, Gardasil-9 offers protection against the HR-HPV types (HPV16, 18, 31, 33, 45, 52, 58 ) that cause~93% of head and neck cancers,~90% of cervical cancers, 90e95% of anal cancers and more than 80% of vaginal, penile and vulvar cancers. The vaccine also protects against HPV6 and 11, types that cause 90% of genital warts (Zhai and Tumban, 2016) . As such, women who are vaccinated with Gardasil-9 vaccine (and also the other HPV vaccines) are still advised to continue screening for other HPV types not included in the vaccine. To broaden protection, researchers have focused on developing next-generation HPV vaccines targeting the HPV minor capsid protein (L2) (Seitz et al., 2014; Jagu et al., 2009; Schellenbacher et al., 2009 ). The minor capsid protein, especially the N-terminus, is highly conserved among diverse HPV types (Gambhira et al., 2007; Kondo et al., 2007) . Nevertheless, normal infection does not induce protective anti-L2 antibody responses because L2 is only transiently exposed on the capsid. During HPV infection, the capsid binds to heparan sulfate proteoglycan (HSPG) on the basement membrane; the capsid then undergoes a series of conformational changes thus transiently exposing the N-terminal portion of L2 (Kines et al., 2009; Selinka et al., 2007) . This conformational change allows the virus to bind to and infect epithelial cells. If neutralizing antibodies, following immunization with L2 antigens are available, they can bind to exposed-neutralizing L2 epitopes thus preventing the infection (Kines et al., 2009; Selinka et al., 2007) . Neutralizing L2 antibodies can cross-protect against diverse HPV types (Roden et al., 2000; Alphs et al., 2008; Pastrana et al., 2005) . However, L2-based immunogens generally elicit much lower antibody titers than L1 VLPs because, unlike L1, L2 cannot self-assemble into VLPs. Different approaches have been explored to enhance the immunogenicity of L2 protein; these include conjugation of an L2 peptide to thioredoxin (Rubio et al., 2009; Seitz et al., 2014) , construction of L2 concatemer proteins derived from different HPV types (Jagu et al., 2009 (Jagu et al., , 2010 , and the display of L2 peptides on different types of VLPs (Schellenbacher et al., 2009; Tumban et al., 2012; Nieto et al., 2012; Tyler et al., 2014; McGrath et al., 2013) . While these approaches enhance cross-protection against diverse HPV types, they do not offer complete protection against all cancer-causing HPV types. In a previous study, we displayed a conserved epitope (representing amino acid 17e31) from HPV16 L2, on the surface of bacteriophage MS2 VLPs. MS2-16L2 VLPs elicited strong antibody response in mice and offered complete protection against HPV16 pseudovirus (PsV) 16 as well as sub-optimal cross-protection against other HPV PsV types (Tumban et al., 2012) . In another study, we showed that immunization with bacteriophage VLPs displaying a consensus L2 epitope (representing amino acid 65e85 derived from an alignment of different HR-HPV types), enhanced crossneutralization, albeit at low titers, against diverse HPV PsV types (PsV 16, 31, 18, 45 and 58) compared to immunization with VLPs displaying a similar epitope derived from HPV16 (Tyler et al., 2014) . These results suggested that the immunogenicity as well as the spectrum of protection against diverse HPV types could be enhanced by displaying conserved or consensus L2 epitopes on the surface of bacteriophage VLPs. In this study, we assessed the spectrum of protection against diverse HPV types following immunization with a mixture of two MS2-L2 VLPs in comparison to immunization with Gardasil-9.
Materials and methods

Cloning, expression and purification of MS2-L2 VLPs
Polymerase chain reaction (PCR) was used, as previously described (Tumban et al., 2011) , to insert different HPV L2 epitopes on the N-terminus of the single-chain dimer of MS2 bacteriophage coat protein. Plasmid pDSP62 (which expresses the single-chain dimer of MS2 coat protein) was used as a PCR template. The following HPV L2 peptides ( Fig. 1A and Table 1 ) representing amino acids (aa) sequences were inserted: a tandem peptide (aa 20e31 from HPV31 L2 & aa 17e31 from HPV16 L2), aa 69e86 from a consensus (cons)L2 sequence, aa 108e122 from a consensus (cons) L2 sequence, and a multivalent epitope representing consL2(108e122)/HPV31L2(20e31)/HPV16L2(17e31). These L2 sequences were engineered into forward PCR primers. A reverse primer, E3.2 (5 0 CGGGCTTTGTTAGCAGCCGG 3 0 ), which anneals downstream of a unique BamHI site in the pDSP62 plasmid was used for all PCR amplifications above. Amplified MS2-L2 PCR fragments were cloned into pDSP62 plasmid using NcoI and BamHI restriction sites and the plasmids were then transformed into C41 E. coli bacteria. All constructs were sequenced to confirm insertions. To express recombinant MS2-L2 proteins, transformed C41 cells were grown at 37 C until the cells reached an optical density (OD) 600 of 0.6. Protein expression was induced with 0.5 mM isopropyl b-D-1-thiogalactopyranoside for 4 h or overnight. Cell pellets were collected and lysed using 0.2% lysozyme solution. Soluble MS2-L2 VLPs were purified by gel filtration on Sepharose CL-4B column.
Characterization of MS2-L2 VLPs
Transmission electron microscopy (TEM) was done as previously published (Tumban et al., 2011) to assess whether all constructs assembled into VLPs. To assess whether the L2 epitopes were displayed on the MS2 bacteriophage VLPs, enzyme-linked immunosorbent assay (ELISA) and Western blot were done. Western blotting was conducted as follows: 100 ng of MS2-L2 VLPs or control MS2 VLPs were run on an SDS-PAGE gel and transferred to polyvinylidene fluoride membranes. The membranes were blocked and 1:5000 dilution of anti-HPV16 L2 (aa 1e88) serum (Tumban et al., 2012) or MS2 serum was added and incubated for 2 h. The membranes were washed and 1:10,000 dilution of horseradish peroxide (HRP)-conjugated goat anti-mouse IgG antibodies added for 1 h. The membranes were then washed and developed using a mixture of SuperSignal West Pico (Lumino/Enhance and Stable Peroxide) solutions. To confirm the Western blot results, ELISA was conducted as follows: Briefly, ELISA plates were coated with 500 ng of purified MS2-L2 VLPs. The wells were blocked and serial dilutions of anti-HPV16 L2 (aa 1e88) serum was added. The plates were incubated for 2 h and 1:5000 dilution of HRP-conjugated goat anti-mouse IgG antibodies was added for 1 h. The plates were developed by adding 3, 3 0 , 5, 5 0 -tetramethylbenzidine (TMB) and the reactivity was determined at OD 450 .
Immunization of mice and characterization of antibody responses
All animal work was conducted in accordance with Institutional Animal Care and Use Committee (IACUC) guidelines. Four Balb/c mice (per group) were immunized intramuscularly (i.m.) with 5 mg each of MS2-16L2 VLPs (displaying aa 17e31 from HPV16) (Tumban et al., 2012) , MS2-31L2 VLPs (displaying aa 17e31 from HPV31) (Tyler et al., 2014) , MS2-31/16L2 VLPs (displaying tandem L2 peptide 20e31 and 17e31 from HPV31 and HPV16, respectively), MS2-consL2(69e86), MS2-consL2(108e122), MS2-consL2(108e122)/ 31L2/16L2, or immunized with a mixture of VLPs [Mixed MS2-L2 VLPs: 5 mg MS2-consL2(108e122)/31L2/16L2 plus 5 mg of MS2-consL2(69e86)]. All VLPs were mixed with alum hydroxide adjuvant prior to immunizations and immunizations were done twice at two-week intervals. Anti-L2 IgG antibody responses in sera were tested by L2 peptide-ELISA using synthetic HPV16L2 (17e31), HPV31L2 (17e31), consL2(69e86), and consL2(108e122) as target antigens. The peptides were conjugated to streptavidin using biotin or SMPH [Succinimidyl 6-((beta-maleimidopropionamido)hexanoate)] and were then used to coat ELISA plates. ELISAs were conducted as described above and the titers of antibodies were determined as the reciprocal of the highest sera dilution with an OD 450 greater than 2-fold compared to that of control sera at the same dilution. (HPVs 16, 18, 26, 31, 33, 34, 35, 39, 45, 51e53, 56, 58, 59, 66, 68, 73 and 82) and low-risk HPV types (HPVs 6, 11, 43, and 44) using Jalview software and T-coffee program. Highly conserved amino acids (conservation) are shown in yellow/gold tall bars whereas less conserved amino acids are shown in tan/chocolate short bars. Glycine (G) at position 85 was not included in designing consensus (69e86) peptide because only HPV 11 had G at this position. "þ" at position 114 was replaced with valine (V) since most HPVs have V at this site. Glutamic acid (E) at 116 and Alanine (A) at 121 were replaced with isoleucine (I) and proline (P), respectively. B) TEM images of purified MS2 VLPs displaying L2 peptides (70,000X). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Table 1 HPV L2 peptides inserted on MS2 VLPs.
Pseudovirus production and purification
HPV PsV types (PsV: 16, 33, 45, 58 ) encapsidating a reporter plasmid [pClucf: encodes both green fluorescence protein (GFP) and luciferase] were produced in 293 TT cells as previously described . Briefly, 293 TT cells were transfected with a mixture of two plasmids (each HPV shell and a pCluf). Fortyeight hours after transfection, cells were lysed and mature PsV was purified on a cesium chloride gradient by ultracentrifugation at 20,000 rpm for 17 h or 40,000 rpm for 4 h.
Cervicovaginal infection with HPV PsVs
Mice were intramuscularly immunized twice each with 5 mg of MS2 control VLPs, MS2 VLPs displaying L2 peptides or with Mixed MS2-L2 VLPs at two-week intervals. In addition to these, another group of mice was immunized with 5 mg of Gardasil-9. All immunizations were done with alum hydroxide adjuvant. Two weeks after the last immunization, mice were subcutaneously treated with 3 mg of Depo-Provera. After five days, mice were vaginally challenged with~6.4 Â 10 6 infectious unit (IU) of PsV. Forty-eight hours post-PsV challenge, mice were vaginally instilled with 0.4 mg of luciferin and imaged with a Caliper IVIS Lumina II as previously described (Tumban et al., 2011 ).
In vitro neutralization assays
Neutralization assays were performed as previously described (Day et al., 2012) . Briefly, HPV PsV18 and PsV33 encapsidating a reporter plasmid (pfwB: expresses GFP) were made in 293 TT cells as above. HPV PsV18 and PsV33 were titered in pgsa-745 cells and virus titers that lead to 20% and 75% infectivity (expression of GFP relative to control cells), respectively, were used in the neutralization assay as followings: extracellular matrix (ECM) from MCF10A cells was deposited in 96-well plates followed by the addition of the PsVs. The ECM-PsVs were incubated overnight followed by the addition of serial-dilutions of sera collected from immunized mice or addition of growth media as control. The plates were incubated for 6 h and pgsa-745 cells were added. Forty-eight hours later, PsV infectivity/neutralizations were assessed by flow cytometry based on the expression levels of GFP in infected cells. The reciprocal of the highest sera dilution that inhibited 50% of PsV infection relative to control sera was considered the neutralization titer.
Statistical analysis
Statistical analyses for ELISA and PsV challenges were determined by unpaired two-tailed t-test and unpaired one-tailed t-test, respectively.
Results
Insertion of multiple L2 epitopes on MS2 coat protein does not affect VLP assembly
We had previously shown that immunization with MS2 bacteriophage VLPs displaying HPV16L2 (17e31) offered complete protection against HPV PsV16 but suboptimal cross-protection against other high-risk HPV PsV types. To enhance protection against these other HPV types, we explored several strategies. First, we constructed recombinant coat proteins displaying a tandem L2 peptide (aa 20e31 from HPV31 and aa 17e31 HPV16) or consensus L2 sequences (representing aa 69e86 or aa 108e122) at the N-terminus of the MS2 coat protein. The consensus sequence was obtained by aligning amino acid sequences from 19 HR-HPV types plus 4 lowrisk types using Jalview software (version 2.9.0b2) and T-coffee program (Fig. 1A) . In a second strategy, we inserted multiple epitopes [consL2(108e122) and the tandem 31L2/16L2 peptide] on the MS2 coat protein. TEM analysis indicated that all these recombinant constructs assembled into VLPs (Fig. 1B and Table 1 ). To confirm that the coat proteins contained L2, VLPs were analyzed by Western blot using anti-MS2 and anti-HPV16 L2 (aa 1e88) serum. As shown in Fig. 2A , anti-HPV 16L2 serum reacted with all VLPs except with MS2-consL2(108e122) and control MS2 VLPs as expected. As expected, anti-MS2 serum reacted with each VLP. The varying sizes of recombinant MS2-L2 protein bands reflect the differences in the sizes of inserted L2 epitopes.
To assess if the L2 peptides were actually displayed on intact VLPs, an ELISA was conducted using MS2-L2 VLPs or control MS2 VLPs as target antigens. As shown in Fig. 2B , anti-HPV16 L2 serum (at a 1:10,240 dilution) reacted with MS2-31/16L2 VLPs and MS2-consL2(108e122)/31L2/16L2 VLPs, and, to a lesser extent (at a 1:640 dilution) with MS2-consL2(69e86) VLPs. These data suggest that the peptides are displayed on the surface of VLPs.
MS2 VLPs displaying multiple L2 epitopes are immunogenic
To assess the immunogenicity of MS2 VLPs displaying the L2 peptides, mice were immunized with two doses (5 mg/dose) of purified MS2-L2 VLPs or control MS2 VLPs. Another group of mice was immunized twice with a mixture of VLPs [Mixed MS2-L2 VLPs; MS2-consL2(108e122)/31L2/16L2 plus MS2-consL2(69e86)] in order to assess whether immunizing with multiple L2 VLPs could enhance the spectrum of protection. In general, all of the VLPs elicited high-titer antibody responses. Sera collected from mice immunized with MS2-16L2, MS2-31L2, MS2-31/16L2, and MS2-consL2(108e122)/31L2/16L2 VLPs had high antibody titers (>10 4 ) against HPV16 and HPV31 L2 peptides (Fig. 3AeB) . Moreover, mice immunized with MS2-consL2(69e86) VLPs had high IgG titers against consL2(69e86) peptide (Fig. 3C ). In contrast, VLPs displaying the consL2(108e122) peptide were less immunogenic and induced lower antibody titers (<10 3 ) (Fig. 3D ). Mice immunized with Mixed MS2-L2 VLPs had similar antibody titers (>10 4 ) against HPV16 L2, HPV31 L2 and consL2(69e86) peptides as mice immunized with individual VLPs (Fig. 3A , B and C), suggesting that mixing the VLPs did not compromise the immunogenicity of individual L2 epitopes.
MS2 VLPs displaying multiple L2 epitopes offered broad protection against HPV PsVs, at levels similar to Gardasil-9 vaccine
To determine whether immunization with MS2-L2 VLPs conferred protection from genital infection with various HPV types, immunized mice were vaginally infected with HPV PsV (16, 31, 45, and 58) and protection efficacies were compared to those of mice immunized with Gardasil-9 or control MS2 VLPs. We assessed cross-protection against HPV PsV31 and 58 because in a previous study (Tumban et al., 2012) we observed suboptimal crossprotection against these PsVs following immunization with MS2-16L2 VLPs. Mice immunized with MS2-16L2, MS2-31L2, MS2-31/ 16L2, MS2-consL2(108e122)/31L2/16L2, and Mixed MS2-L2 VLPs showed protection against HPV PsV31, at levels similar to Gardasil-9 (which contains HPV31 VLPs) vaccine-immunized mice (Fig. 4A) ; Moreover, almost complete protection were observed against PsV58, PsV45, and PsV16 challenge (Fig. 4BeD ). Mice immunized with MS2-consL2(69e86) VLPs showed only slight protection (not significant) against the HPV PsV types tested, and MS2-consL2(108e122) was not protective. Mixed MS2-L2 VLPs offered the best protection against all PsV types except against PsV58.
The in vitro neutralization assay is an alternative method that Mice were immunized twice with 5 mg of MS2-L2 VLPs or control MS2 VLPs at two-week intervals. Sera were collected two weeks after the last immunization and anti-L2 peptide IgG titers were determined by end-point dilution ELISA using: A) 16L2 (17e31) peptide, B) 31L2 (17e31) peptide, C) consensus L2(108e122) peptide, and D) consensus L2(69e86) peptide as target peptides. Titers were determined as the reciprocal of highest sera dilutions at which reactivity of experimental sera was at least twice that of control MS2 sera. "Mixed MS2-L2 VLPs" serum was collected from mice immunized with a mixture of consL2(108e122)/31L2/16L2 and consL2(69e86) VLPs. Each datum (circles, squares, rectangles, and triangles, etc.) represents titer in an individual mouse and lines stand for the geometric mean for each group.
can be used to test the neutralization efficacy (i.e. predict protection potentials) of candidate HPV vaccines. To test the neutralizing potential of our MS2-L2 VLPs with other HPV types, sera from mice immunized with VLPs (MS2-31/16L2 and Mixed MS2-L2) that offered the best protection against vaginal infection were used in an in vitro neutralization assay against PsV18 and PsV33. Compared to control MS2 sera, sera from mice immunized with MS2-31/16L2 or Mixed MS2-L2 VLPs neutralized PsV18 and PsV33 at levels similar to sera from mice immunized with Gardasil-9 (Fig. 5) . These results show that MS2-31/16L2 and Mixed MS2-L2 VLPs sera are protective in vivo and in vitro against infection by diverse HPV types.
Discussion
Current HPV vaccines protect mostly against the HPV types included in the vaccines (Zhai and Tumban, 2016) . Given the fact that protection from HPV infections is not 100%, patients vaccinated with any of the HPV vaccines are still recommended to continue cervical cancer screening. The recommended screening is very /sr) of luciferase expression at the genitals was determined using Living Image 3.2 software. Each datum represents the radiance value of an individual mouse and the lines stand for the average geometric mean for each group. Red dashed lines highlight MS2-L2 VLPs efficacy in comparison to Gardasil-9 vaccine. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Fig. 5 . MS2-L2 sera neutralize HPV PsV18 and PsV33. Titers of HPV PsV18 and PsV33 that led to 20% and 75% infectivity, respectively, of pgsa-745 cells were separately incubated with serial-dilutions of sera collected from mice immunized with MS2-L2 VLPs or controls. Incubated PsV and sera were then used to infect pgsa-745 cells. Fortyeight hours after infection, PsV neutralization (based on GFP expression levels) was determined by flow cytometry. Bars indicate the reciprocal of the highest sera dilution at which at least 50% HPV PsV was neutralized compared to controls with no sera. MS2 control sera neutralizing titers were <50. crucial for HIV/AIDS patients given the immunocompromised nature of their immune system, their propensity to be co-infected with up to 10 HR-HPV types (Levi et al., 2002; McKenzie et al., 2014) , and the risk for their HPV infections to progress to invasive cancer 6e15 years earlier than non-HIV patients (Moodley et al., 2006; Moodley et al., 2001) . Thus, there is a need to develop an HPV vaccine with the potential to offer complete protection against HPV-associated cancers, especially in HIV/AIDS patients. We had previously reported that a thermostable bacteriophage MS2 VLPs displaying peptide 17e31 from HPV16 offered complete protection against HPV PsV16 and other HPV PsVs, but suboptimal protection against two important heterologous HPV types (HPV31 and HPV58) (Tumban et al., 2012 (Tumban et al., , 2015 . To enhance protection against some of these heterologous HPV types, we generated for the first time, VLPs [MS2-31/16L2 and MS2-consL2(108e122)/31L2/16L2] displaying concatemers of two or three L2 epitopes, respectively. In addition to these, we developed VLPs [MS2-consL2(69e86), MS2-consL2(108e122)] displaying consensus sequences. Anti-HPV16 L2 serum reacted with all the MS2-L2 VLPs (confirming the display of peptides on VLPs) except for VLPs displaying consL2(108e122) ( Fig. 2A and B) . Lack of reactivity with MS2-consL2(108e122) VLPs was expected because the HPV16 L2 (aa 1e88) serum does not include consL2(108e122) epitope. The reactivity of anti-HPV16 L2 serum with MS2-consL2(69e86) VLPs (compared with other L2-VLPs) was low. This could be explained by the fact that HPV16 L2, from which the serum was generated is 80% identical to 31L2 (at aa 17e31) unlike peptide 69e86 of HPV16 L2, which is only 72% identical to consL2(69e86).
Mice immunized with VLPs displaying concatemers, consensus sequences [except MS2-consL2(108e122)], and Mixed MS2-L2 VLPs [MS2-consL2(108e122)/31L2/16L2 plus MS2-consL2(69e86)] elicited high anti-L2 antibody titers (Fig. 3) , which protected/ neutralized six HPV PsV types (16, 18, 31, 33, 45, 58) at levels similar to Gardasil-9 vaccine (Figs. 4 and 5) . Mixed MS2-L2-immunized mice offered the best protection except against PsV58; we are not sure why partial protection was observed given the fact that 31L2 and 16L2 (17e31) share~87% and 80% amino acid identity, respectively, with 58L2 at the same epitope. MS2-16L2 VLPs in this study offered good protection (although a little less compared to MS2-31L2 VLPs) against PsV31 and PsV58, whereas we had observed less protection in a previous study (Tumban et al., 2012) . It is likely that mice in our previous study were challenged with higher PsV dose compared to this study. For example, control MS2 mice challenged with PsV31 in our previous study had a higher geometric mean average radiance (GMAR 10 5.5 ) compared to MS2 control mice in this study with GMAR of 10 4.8 . Irrespective of these differences, these results suggest that immunization with a tandem L2 peptide or a mixture of L2 peptides does not compromise the immunogenicity of individual epitopes. While robust responses were observed with the VLPs displaying peptide 17e31 (single or tandem peptide), little protection was observed in mice immunized with VLPs displaying peptide consL2(69e86) and no immune responses were observed in mice immunized with VLPs displaying peptide consL2(108e122). It was surprising that no significant protection was observed in mice immunized with the MS2-consL2(69e86) given the fact that mice had high anti-L2 antibody titers against this peptide. A previous study had shown that sera (at 1:1000 dilution) from mice immunized with Qb bacteriophage VLPs displaying a similar conjugated consensus L2 peptide neutralized HPV PsV31, 45, 58 (Tyler et al., 2014) . The discrepancy in the results could be explained by the fact that the previous study used a slightly longer consensus sequence (65e85), which included 4 additional amino acids (GTGG) that are highly conserved amongst HPV types. We attempted here to insert (genetically) the same epitope on the coat protein of MS2; however, no expression of the fusion protein was detected (data not shown). With respect to consensus peptide 108e122, we think MS2-consL2(108e122) was not immunogenic because the peptide may not have been properly displayed on the VLPs; previous studies had shown that the isolated peptide contains neutralizing epitopes (Kondo et al., 2007; Tyler et al., 2014) . Unfortunately, we could not confirm genetic display on MS2 due to lack of polyclonal antibodies that include peptide 108e122.
Conclusions
In summary, we have shown that inserting a concatemer of two or three L2 peptides on MS2 coat proteins does not affect the ability of the coat proteins to assemble into VLPs. Additionally, the L2 epitopes are displayed on the VLPs and immunizations with a mixture of MS2 VLPs displaying multiple L2 epitopes do not compromise the immunogenicity of each individual epitope on the VLPs. MS2 VLPs displaying the tandem L2 peptide, (20e31) from HPV31 and (17e31) from HPV16, cross-protected/neutralized selected HR-HPV PsV types, suggesting that this is an excellent approach to achieve broader protection against more HPV types. Moreover, mixing MS2-consL2(108e122)/31L2/16L2 with MS2-consL2(69e86) VLPs offered protection/neutralization at levels similar to Gardasil-9 vaccine. These MS2-L2 VLPs are expressed and purified from bacteria (compared to current vaccines produced in yeast and insect cells), suggesting that the MS2-L2 VLPs may be cheaper compared to Gardasil-9. Thus, the MS2-L2 VLPs developed in this study may be applicable in developing countries in terms of cost and in spectrum of protection. The Vaccine Alliance (Gavi) currently provides HPV vaccines (Gardasil-4 and Cervarix) to developing countries at a subsidized rate ($4-$5/dose) (Zhai and Tumban, 2016) . Nevertheless, these vaccines protect mostly against HPV16 and HPV18, which cause~70% of cervical cancer, 53e79% of penile cancer (Gardasil-4 also protects against HPV6 and HPV11, which cause 90% of genital warts). MS2-L2 VLPs may be used in developing countries as an alternative HPV vaccine to offer broad protection against HPV types (16, 18, 31, 33, 45 , and 58) associated with~87% of cervical cancers and more than 90% of head and neck cancers. Thus, these MS2-L2 VLPs are candidates for low valency yet broadly cross-protective HPV vaccines that should be assessed further for protection against more HPV types especially those that may be more common in HIV patients.
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